The aims of the cohort study were to reveal the long-term trend and new characteristics of population-based epidemic of cardiovascular disease (CVD) and risk factors, develop the individualized risk assessment tool which can be applied to clinical and prevention practice in China, examine and present the problems and barriers in primary prevention of major CVD and propose and assess the effectiveness of prevention policies and strategies before implementation.
General Information of Study
Name Chinese Multi-Provincial Cohort Study Project Number CCC2018051601 Website N.A. Investigators Institutions Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases Contacts Funding China National Grant on Science and Technology (85-915-01-02) National Science & Technology Pillar Programduring the 11th Five-year Plan Period (2006BAI01A01 and 2006BAI01A02) National Science & Technology Pillar Program during the 12th Five-Year Plan Period (2011BAI09B01 and 2011BAI11B03） National Key Research and Development Programs（2016YFC0900902） Objectives The aims of the cohort study were to reveal the long-term trend and new characteristics of population-based epidemic of cardiovascular disease (CVD) and risk factors, develop the individualized risk assessment tool which can be applied to clinical and prevention practice in China, examine and present the problems and barriers in primary prevention of major CVD and propose and assess the effectiveness of prevention policies and strategies before implementation. Start Date Jan 3rd,1992 End Date Ongoing
Number of Participants 21949 Age Range 35-84 Geographic Distribution Beijing,Tianjin, Inner Mongolia, Heilongjiang, Liaoning, Shanghai, Ningxia, and Sichuan General Information of Study Design and Sample Methods A multistage sampling method was used. First,the centers were selected nonrandomly. Next, a stratified random sampling for each sex and 10-year age group was performed in each center for the baseline survey。 Inclusion Criteria In 1992, aged 35-64 years . From 1996 to 1999, participants aged 35-64 years were added, and participants aged 35-84 years were added in 2003 Exclusion Criteria participants with CVD at baseline were excluded
Key Achievements The cohort help the research team find the long term changing patterns of epidemics of coronary heart disease (CHD) and stroke, which included the decreasing incidence rate of hemorrhagic stroke, increasing rates of ischemic stroke and CHD, and the increasing epidemics of new metabolic risk factors in addition to uncontrolled classical risk factors. The findings highlight the importance of the prevention of ischemic cardiovascular disease (CVD) in next several decades and the necessity to attach importance from only hypertension to cholesterol, obesity and diabetes and smoking among Chinese population as well.
The individualized risk assessment tool for Chinese population were built based on the data from this cohort, and provided evidence for establishment of clinical criteria of diagnosis and risk stratification for hypertension, dyslipidemia and obesity prevention, which have been adopted in several national and international guidelines.
Based on the massive multi-dimensional data, we established several macro-predictive models and policy models to identify quantitatively the unique patterns of CVD epidemic at different social-economic periods in the past, present and future and provide the scientific support for the evidence-based decision making process for CVD primary prevention in China.
Marker Papers 1. Liu J, Hong Y, D'Agostino RB Sr, Wu Z, Wang W, Sun J, Wilson PW, Kannel WB, Zhao D. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA.2004 Jun 2;291(21):2591-9.
2.Qi Y, Fan J, Liu J, Wang W, Wang M, Sun J, et al. Cholesterol-overloaded HDL particles are independently associated with progression of carotid atherosclerosis in a cardiovascular disease-free population: a community-based cohort study. J Am Coll Cardiol.65 (2015) 355-63.
3.Liu J, Grundy SM, Wang W, Smith SC, Vega GL, Wu Z, et al. Ethnic-Specific Criteria for the Metabolic Syndrome: Evidence from China. Diabetes Care.29 (2006) 1414-6.
4.Xie W, Liu J, Wang W, Wang M, Qi Y, Zhao F, et al. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study. Int J Cardiol.215 (2016) 293-8.
5.Qi Y, Liu J, Wang W, Wang M, Zhao F, Sun J, Liu J, Zhao D. Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk: A community-based cohort study. J Clin Lipidol. 2017 Nov 14. doi: 10.1016/j.jacl.2017.11.003.
6.Liu J, Grundy SM, Wang W, Smith SC, Lena Vega G, Wu Z, et al. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. American Heart Journal.153 (2007) 552-8.
7.Ren J, Grundy SM, Liu J, Wang W, Wang M, Sun J, Liu J, Li Y, Wu Z, Zhao D. Long-term coronary heart disease risk associated with very-low-density lipoprotein cholesterol in Chinese: the results of a 15-Year Chinese Multi-Provincial Cohort Study (CMCS). Atherosclerosis. 2010 Jul;211(1):327-32.
8. Wang Y, Liu J, Wang W, Wang M, Qi Y, Xie W, Li Y, Sun J, Liu J, Zhao D. Lifetime risk for cardiovascular disease in a Chinese population: the Chinese Multi-Provincial Cohort Study. Eur J Prev Cardiol. 2015 Mar;22(3):380-8.
9.Xie W, Liu J, Wang W, Wang M, Li Y, Sun J, et al. Five-year change in systolic blood pressure is independently associated with carotid atherosclerosis progression: a population-based cohort study. Hypertension Research.37 (2014) 960-5.
10.Zhao D, Grundy SM, Wang W, Liu J, Zeng Z, Wang W, et al. Ten-Year Cardiovascular Disease Risk of Metabolic Syndrome Without Central Obesity in Middle-Aged Chinese. The American Journal of Cardiology.100 (2007) 835-9.
Strength Participants were free of cardiovascular disease when were enrolled in the study. Now the cohort was followed up more than 20 years. Weakness None
General Information of Baseline Investigation
Variables of Baseline Investigation
General Information of Follow-up Investigation
Variables of Follow-up Investigation